BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, July 9, 2025
Home » Authors » David Ho

Articles by David Ho

Alvogen eyes large opportunity in Korea in deal for Vivus' Qsymia

Sep. 20, 2017
By David Ho
HONG KONG – Alvogen Korea Ltd. has announced an agreement for exclusive rights to license, sell and market Vivus Inc.'s obesity drug, Qsymia (phentermine/topiramate), in South Korea, a deal expected to shore up the company's strong position in the Korean market while adding to its obesity portfolio, said Petar Vazharov, Alvogen's Asia-Pacific executive vice president.
Read More

Shanghai Fosun makes progress on stalled Gland Pharma purchase

Sep. 19, 2017
By David Ho

HONG KONG – Shanghai Fosun Pharmaceutical Group Co. Ltd. has made progress on its proposed purchase of the majority stake in India's Gland Pharma Ltd., with a recent amendment stating it would acquire 74 percent of the interest in the Hyderabad-based pharmaceutical company for $1.09 billion, instead of the original proposed 86 percent for $1.26 billion.


Read More

Alvogen eyes large opportunity in Korea in deal for Vivus' Qsymia

Sep. 18, 2017
By David Ho
HONG KONG – Alvogen Korea Ltd. has announced an agreement for exclusive rights to license, sell and market Vivus Inc.'s obesity drug, Qsymia (phentermine/topiramate), in South Korea, a deal expected to shore up the company's strong position in the Korean market while adding to its obesity portfolio, said Petar Vazharov, Alvogen's Asia-Pacific executive vice president.
Read More

Shanghai Sanyou raises $14M in venture capital for R&D

Sep. 14, 2017
By David Ho

Hanall grants China rights to Harbour for two novel biologics

Sep. 14, 2017
By David Ho
HONG KONG – Chinese biotech company Harbour Biomed Therapeutics Ltd. has entered a collaboration and licensing agreement with South Korea's Hanall Biopharma Co. Ltd. for novel biologics. Under the agreement, Harbour, of Shanghai, will have the rights to develop, manufacture and commercialize HL-161 and HL-036 for the Greater China market, which includes the territories of Hong Kong, Macau and Taiwan.
Read More

Abbott moves to withdraw stents from India, again

Sep. 13, 2017
By David Ho

Orbimed targeting China, India investments with record $551M Asia fund

Sep. 12, 2017
By David Ho

HONG KONG – Orbimed said it raised around $551 million in its third Asia-focused private equity fund, Orbimed Asia Partners III (OAP3), nearly doubling the $325 million raised for the previous fund in September 2014.


Read More

Orbimed raises record $551M for third Asia health care fund

Sep. 11, 2017
By David Ho

Orbimed targeting China, India investments with record $551M Asia fund

Sep. 11, 2017
By David Ho
HONG KONG – Orbimed said it raised around $551 million in its third Asia-focused private equity fund, Orbimed Asia Partners III (OAP3), nearly doubling the $325 million raised for the previous fund in September 2014.
Read More

China's 3Sbio acquires Therapure Biomanufacturing in $290M deal

Sep. 11, 2017
By David Ho
HONG KONG – 3Sbio Inc. inked a proposed asset purchase agreement worth $290 million for the contract development and manufacturing organization (CDMO) business of Canada's Therapure Biopharma Inc., a deal that would mark 3Sbio's first foray into the North American biopharmaceutical sector.
Read More
Previous 1 2 … 62 63 64 65 66 67 68 69 70 71 72 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 8, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 8, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 8, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • 3D rendering of a molecular glue mediating the interaction between two proteins

    With surface mimicry, molecular glues shed hairpin need

    BioWorld Science
    Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing